Articles

• NMO-IgG predicts the outcome of recurrent optic neuritis

  M. Matiello, V. A. Lennon, A. Jacob, S. J. Pittock, C. F. Lucchinetti, D. M. Wingerchuk, B. G. Weinshenker

  • Abstract
  • Full Text
  • Full Text (PDF)

  CME Course
• VBM anticipates the rate of progression of Alzheimer diseaseA 3-year longitudinal study

  S. Kinkingnéhun, M. Sarazin, S. Lehéricy, E. Guichart-Gomez, T. Hergueta, B. Dubois

  • Abstract
  • Full Text
  • Full Text (PDF)
• An aberrant protein complex in CSF as a biomarker of Alzheimer disease

  M. A. Lovell, B. C. Lynn, S. Xiong, J. F. Quinn, J. Kaye, W. R. Markesbery

  • Abstract
  • Full Text
  • Full Text (PDF)
• Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology

  Z. Arvanitakis, F. Grodstein, J. L. Bienias, J. A. Schneider, R. S. Wilson, J. F. Kelly, D. A. Evans, D. A. Bennett

  • Abstract
  • Full Text
  • Full Text (PDF)
• Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder

  A. Vanderver, Y. Hathout, J. Maletkovic, E. S. Gordon, M. Mintz, M. Timmons, E. P. Hoffman, L. Horzinski, F. Niel, A. Fogli, O. Boespflug-Tanguy, R. Schiffmann

  • Abstract
  • Full Text
  • Full Text (PDF)
• A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

  M. Stacy, D. Silver, T. Mendis, J. Sutton, A. Mori, P. Chaikin, N. M. Sussman

  • Abstract
  • Full Text
  • Full Text (PDF)
• Determinants of disability and quality of life in mild to moderate Parkinson disease

  D. Muslimović, B. Post, J. D. Speelman, B. Schmand, R. J. de Haan

  • Abstract
  • Full Text
  • Full Text (PDF)
• Neurologic consequences of autoimmune polyglandular syndrome type 1

  Joseph R. Berger, Allison Weaver, John Greenlee, George E. Wahlen

  • Abstract
  • Full Text
  • Full Text (PDF)